



FO716163 Receipt

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/029,115	
	Filing Date	October 19, 2001	
	First Named Inventor	Luo, Ying	
	Art Unit	1635	
	Examiner Name	Terra C. Gibbs	
Total Number of Pages in This Submission		Attorney Docket Number	021044-005600US

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input checked="" type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i> Petition to Correct Inventorship under 37 CFR 1.48(a); Copy of Filing Receipt with Red-Inked Changes; Declarations of Luo, Yu, Xu and Leo; Application Data Sheet; Statements under 37 CFR 1.48(a) of Yu, Xu, Leo, Fu and Shen; Assignment for Recordation from Luo, Yu, Xu and Leo to Rigel Pharmaceuticals, Incorporated; Assignment Recordation Form Cover Sheet; Consent of Assignee for Correction of Inventorship; Return Postcard
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Beth L. Kelly Reg. No. 51,868
Signature	
Date	July 1, 2003

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Jo Ann Honcik Dallara		
Signature		Date	July 1, 2003
SF 1473144 v1			

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL
for FY 2003**

Effective 01/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 225

Complete if Known

Application Number	10/029,115
Filing Date	October 19, 2001
First Named Inventor	Luo, Ying
Examiner Name	Terra C. Gibbs
Art Unit	1635
Attorney Docket No.	021044-005600US

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ MoneyOrder ☐ Other ☐ None
☒ Deposit Account:

Deposit
Account
Number

20-1430

Deposit
Account
Name

Townsend and Townsend and Crew LLP

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments
☒ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1)

(\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims		Fees from below		Fee Paid	
Total Claims		**	=		X		
Independent Claims		**	=		X		
Multiple Dependent					X		

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	55
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	130
1807	50	1807	50	Petitions related to provisional applications	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	40
1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	


Other fee (specify)

*Reduced by Basic Filing Fee Paid SUBTOTAL (3)

(\$)225

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Beth L. Kelly	Registration No. (Attorney/Agent)	51,868	Telephone	415-576-0200
Signature				Date	July 1, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. SF 1473382 v1

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



#15

hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 021044-005600US

Assistant Commissioner for Patents, P.O. Box 1450
Washington, D.C. 20231-~~Alexandria~~, VA 22313-1450

On July 1, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Jo Dallas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ying Luo et al.

Application No.: 10/029,115

Filed: October 19, 2001

For: NOVEL GERMINAL KINASE
CENTER PROTEINS, COMPOSITIONS,
AND METHODS OF USE

STATEMENT UNDER 37 C.F.R. §1.48(a)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I, Mary Shen, state that it was through error without deceptive intent that I was named as an inventor in the above-referenced patent application.

Dated: 03/20/2003

By Mary Mary Luo Shen
Mary Shen

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
BLK:blk



#15

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 021044-005600US PATENT

Assistant Commissioner for Patents, P.O. Box 1450
Washington, D.C. 20231 Alexandria, VA 22313-1450

On July 1, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Joe Dallara

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ying Luo et al.

Application No.: 10/029,115

Filed: October 19, 2001

For: NOVEL GERMINAL KINASE
CENTER PROTEINS, COMPOSITIONS,
AND METHODS OF USE

STATEMENT UNDER 37 C.F.R §1.48(a)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I, C. Alan Fu, state that it was through error without deceptive intent that I was named as an inventor in the above-referenced patent application.

Dated: 4/25/2003

By C. Alan Fu
C. Alan Fu

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
BLK:blk



#15

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 021044-005600US

~~Assistant~~ Commissioner for Patents, P.O. Box 1450
Washington, D.C. 20231 Alexandria, VA 22313-1450

On July 1, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Jo Dallara

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ying Luo et al.

Application No.: 10/029,115

Filed: October 19, 2001

For: NOVEL GERMINAL KINASE
CENTER PROTEINS, COMPOSITIONS,
AND METHODS OF USE

STATEMENT UNDER 37 C.F.R. §1.48(a)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I, Cindy Leo, state that it was through error without deceptive intent that I was not named as an inventor in the above-referenced patent application.

Dated: 4/28/03

By Cindy Leo

Cindy Leo

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
BLK:dk



#15

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 021044-005600US

~~Assistant~~ Commissioner for Patents, P.O. Box 1450
~~Washington, D.C. 20231~~ Alexandria, VA 22313-1450

On July 1, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Jo Dallara

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ying Luo et al.

Application No.: 10/029,115

Filed: October 19, 2001

For: NOVEL GERMINAL KINASE
CENTER PROTEINS, COMPOSITIONS,
AND METHODS OF USE

STATEMENT UNDER 37 C.F.R §1.48(a)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I, Xiang Xu, state that it was through error without deceptive intent that I was not named as an inventor in the above-referenced patent application.

Dated: 3-20-03

By Xiang Xu

Xiang Xu

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
BLK:blk



#15

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 021044-005600US

~~Assistant~~ Commissioner for Patents, P.O. Box 1450
~~Washington, D.C. 20231~~ Alexandria, VA 22313-1450

On July 1, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ying Luo et al.

Application No.: 10/029,115

Filed: October 19, 2001

For: NOVEL GERMINAL KINASE
CENTER PROTEINS, COMPOSITIONS,
AND METHODS OF USE

STATEMENT UNDER 37 C.F.R §1.48(a)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I, Simon Yu, state that it was through error without deceptive intent that I was not named as an inventor in the above-referenced patent application.

Dated: 3-20-03

By [Signature]
Simon Yu

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
BLK:blk



#15

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 021044-005600US

~~Assistant~~ Commissioner for Patents, P.O. Box 1450
~~Washington, D.C. 20231~~ Alexandria, VA 22313-1450

On July 1, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: J. Dallas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ying Luo et al.

Application No.: 10/029,115

Filed: October 19, 2001

For: NOVEL GERMINAL KINASE
CENTER PROTEINS, COMPOSITIONS,
AND METHODS OF USE

**CONSENT OF ASSIGNEE FOR
CORRECTION OF INVENTORSHIP**

UNDER 37 C.F.R. §1.48(a)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The assignee of the above-identified patent, Rigel Pharmaceuticals, Inc., consents to amending the subject patent application to add Simon Yu, Xiang Xu, and Cindy Leo as inventors to the above-identified patent application; and to remove C. Alan Fu and Mary Shen as inventors to the above-identified patent application.

Ying Luo et al.
Application No.: 10/029,115
Page 2

PATENT

In accordance with 37 CFR § 3.73, a copy of the executed assignment submitted for recording is enclosed to establish Rigel Pharmaceuticals, Inc.'s ownership of the above-referenced patent application.

RIGEL PHARMACEUTICALS, INC.

Date: May 29, 2003

By: 

Name: Dolly A. Vance

General Counsel, VP Intellectual Property

Title:

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
BLK:blk
SF 1424714 v1



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/029,115	10/19/2001	1653	953	A- 70229/RMS/DHR	19	15	12

DORSEY & WHITNEY LLP
Suite 3400
Four Embarcadero Center
San Francisco, CA 94111-4187



CONFIRMATION NO. 2856

UPDATED FILING RECEIPT



OC000000008589367

Date Mailed: 08/08/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Ying Luo, Shanghai, CHINA;

~~G. Alan Fu, Union City, CA; remove~~~~Mary Shen, Newark, CA; remove~~

add { Simon Yu, Newark, CA;
Xiang Xu, South San Francisco, CA;
Cindy Leo, San Francisco, CA

D mestic Priority data as claimed by applicant

F reign Applications

If Required, Foreign Filing License Granted 03/14/2002

Projected Publication Date: 04/24/2003

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Novel germinal center kinase proteins, compositions and methods of use

Preliminary Class

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).